

1 **Inspiratory Muscle Strength Training to Improve Cardiometabolic Health in**  
2 **Patients with Type 2 Diabetes Mellitus: Protocol for the Diabetes Inspiratory**  
3 **Training (DIT) Clinical Trial**

4

5

6 Baylee L. Reed<sup>1</sup>, Dallin Tavoian<sup>1</sup>, E. Fiona Bailey<sup>1</sup>, Janet L. Funk<sup>2</sup>, Dawn K.  
7 Coletta<sup>1,2,3,#\*</sup>

8

9

10 <sup>1</sup>Department of Physiology, University of Arizona, Tucson, Arizona, USA

11 <sup>2</sup>Department of Medicine, Division of Endocrinology, University of Arizona, Tucson,  
12 Arizona, USA

13 <sup>3</sup>Center for Disparities in Diabetes, Obesity and Metabolism, University of Arizona,  
14 Tucson, Arizona, USA

15

16 #Current address: University of Arizona College of Medicine, Department of Medicine,  
17 PO Box 245035, 1501 N. Campbell Ave, Tucson, AZ 85724-5035

18 Trial Registration: This trial is registered on [clinicaltrials.gov](https://clinicaltrials.gov); NCT05643768

19 Protocol Version: 1.0

20 Funding: This study will be supported by a SPARK grant from the College of Medicine  
21 at the University of Arizona, Tucson.

22

23 **\*Corresponding Author**

24 Email: [dcoletta@arizona.edu](mailto:dcoletta@arizona.edu) (DKC)

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 26 **Abstract**

27 Type 2 diabetes mellitus (T2DM) is a complex, chronic metabolic disease that carries  
28 with it a high prevalence of comorbid conditions, making T2DM one of the leading  
29 causes of death in the U.S. Traditional lifestyle interventions (e.g., diet, exercise) can  
30 counter some adverse effects of T2DM; however, participation in these activities is low  
31 with reasons ranging from physical discomfort to lack of time. Thus, there is a critical  
32 need to develop novel management strategies that effectively reduce cardiometabolic  
33 disease risk and address barriers to adherence. High-resistance inspiratory muscle  
34 strength training (IMST) is a time-efficient and simple breathing exercise that  
35 significantly reduces systolic and diastolic BP and improves vascular endothelial  
36 function in adults with above-normal blood pressure. Herein, we describe the study  
37 protocol for a randomized clinical trial to determine the effects of a 6 week IMST  
38 regimen on glycemic control and insulin sensitivity in adults with T2DM. Our primary  
39 outcome measures include fasting plasma glucose, fasting serum insulin, and insulin  
40 sensitivity utilizing homeostatic model assessment for insulin resistance (HOMA-IR).  
41 Secondary outcome measures include casual (resting) systolic BP and endothelial-  
42 dependent dilation. Further, we will collect plasma for exploratory proteomic analyses.  
43 This trial seeks to establish the cardiometabolic effects of 6 weeks of high-resistance  
44 IMST in patients with T2DM.

45

46

## 47 **Introduction**

48           Type 2 diabetes mellitus (T2DM) is at epidemic proportions in the United  
49 States, affecting 37.3 million people (or 11.3% of the population) [1]. In 2017, the  
50 annual economic cost was \$327 billion, making it one of the most expensive chronic  
51 conditions in the U.S. [2]. T2DM is a chronic, obesity-associated metabolic disorder  
52 characterized by glucose dysregulation, insulin resistance, and beta-cell defects [3,4].  
53 Adults with T2DM are likely to develop vascular endothelial dysfunction and vascular  
54 inflammation, increasing their risk of cardiovascular disease (CVD) and the occurrence  
55 of cardiac events [5]. First-line T2DM treatments include lifestyle modifications, such  
56 as dietary changes and exercise [6], the benefits of which are well established in T2DM  
57 patients [7,8]. However, adherence to conventional exercise is low, as only 41% of U.S.  
58 adults with T2DM meet current aerobic exercise guidelines, and only 12% meet  
59 resistance exercise guidelines, compared to the general population, with participation  
60 rates at 52% and 21%, respectively [9]. This is due in part to barriers such as physical  
61 discomfort and lack of time [10,11]; thus, new regimens designed to overcome these  
62 barriers are needed.

63           Recently, a novel and time-efficient respiratory exercise called Inspiratory  
64 Muscle Strength Training (IMST) was developed [12]. IMST is distinct from other  
65 traditional forms of exercise due to its abbreviated training format (i.e., 5 minutes daily)  
66 and is performed using a hand-held device while seated or standing [12]. With just six  
67 weeks of training (5 days/week), high resistance-IMST has been shown to lower  
68 systolic blood pressure (systolic BP) by ~9 mmHg in normotensive and hypertensive  
69 adults [13]. Furthermore, it has improved endothelial-dependent dilation (EDD) by  
70 45% in older adults with impaired endothelial function [14]. These vascular effects of  
71 IMST are believed to reduce the risks of CVD, the number one cause of death in people

72 with T2DM [15]. IMST is safe and well tolerated, with adherence rates >90% in diverse  
73 populations [14,16], and thus presents a manageable introductory or adjunctive  
74 program for improving cardiometabolic health in T2DM patients who have difficulty  
75 maintaining a traditional exercise program. However, the effects of IMST on glycemic  
76 control and insulin sensitivity, as well as systolic BP and EDD, are unknown in patients  
77 with T2DM.

78       Vascular endothelial function and metabolic function are closely linked [17].  
79 The vascular endothelium produces nitric oxide (NO), which is released in response to  
80 increased arterial wall shear stress (i.e., increased blood flow) [18]. Among its various  
81 functions, NO enhances glucose uptake into cells and improves insulin sensitivity [19].  
82 T2DM is associated with impairments in endothelial function, including reduced NO  
83 production and increased vascular inflammation [20]. High resistance-IMST is a  
84 potentially effective tool to combat T2DM-associated endothelial dysfunction, as it has  
85 been shown to increase NO bioavailability and reduce oxidative stress [14] — key  
86 adaptations that could underly the improved metabolic health. The latter is especially  
87 significant given the link to metabolic syndrome, which encompasses insulin resistance,  
88 impaired glucose metabolism, and hypertension [21] and, therefore, heightens the risks  
89 for cardiac events or stroke [21].

90       The potential for IMST to elicit cardiometabolic adaptations in patients with  
91 T2DM warrants assessment. Accordingly, we outline a plan to interrogate the effects  
92 of 6 weeks of high-resistance IMST on glycemia (fasting plasma glucose), insulin  
93 sensitivity/resistance (fasting serum insulin and Homeostasis Model Assessment  
94 [HOMA-IR; ratio of fasting insulin/glucose]), causal (resting) BP, and NO-mediated  
95 EDD in T2DM patients. Participants will be randomized into either high-resistance

96 (experimental) or low-resistance (control) groups and complete IMST at home 5  
97 days/week for 6 weeks, with each session lasting ~5 minutes [22].

98 We will study T2DM patients before and after 6 weeks of high-resistance IMST  
99 to test the hypotheses that (1) fasting plasma glucose will decrease, and insulin  
100 sensitivity will improve, (2) Casual (resting) systolic BP will decrease, and (3) high-  
101 resistance IMST will improve EDD resulting in clinically-meaningful improvements  
102 (i.e., >1% unit change) [23]. Lastly, we will consent and collect DNA for banking for  
103 future studies and plasma to perform quantitative proteomics to evaluate novel protein  
104 expression changes pre- versus post-IMST. Our goal from the exploratory proteomic  
105 analyses is to identify mechanisms that underlie the training.

106

## 107 **Materials and Methods**

### 108 **Study Design**

109 The Diabetes Inspiratory Training (DIT) study is a randomized, sham-controlled,  
110 exploratory clinical trial examining the effects of IMST in 24 adults with T2DM. This  
111 is a 6 week intervention study design. An outline of the study is shown in Figure 1.

112

### 113 **Figure 1.** Study Flow for the DIT Study

114

115 Participants will perform 5 sets of 6 breaths per day, 5 days per week, at either high  
116 relative resistance (75% of maximal inspiratory pressure in cmH<sub>2</sub>O, (PI<sub>max</sub> )) or low  
117 relative resistance (15% of PI<sub>max</sub>) [22].

118

### 119 **Participants and Interventions**

120 **Study Setting and Study Population**

121 The DIT Study will be conducted at the Clinical and Translational Sciences (CATS)  
122 Research Center at the University of Arizona. Participants will be pre-screened over the  
123 phone to determine their eligibility using the inclusion and exclusion criteria (Table 1).

124 **Table 1.** Inclusion and Exclusion Criteria for DIT Study

Inclusions	Exclusions
18+ years old	Current smoker (tobacco / cannabis)
Diagnosed with type 2 diabetes by physician	Uncontrolled medical condition (e.g., cancer)
Fasting plasma glucose levels $\geq 126$ mg/dl and $\leq 240$ mg/dl	Myocardial infarction or stroke within the previous 12 months
SBP between 120-169 mmHg	Performs regular aerobic exercise ( $>4$ bouts/week)
Stable dose of medication (3 months on same dose)	DBP $>100$ or $<60$ mmHg
Weight stable in the prior 3 months ( $< 3$ kg weight change) and willing to remain weight stable throughout the study	SBP $<120$ or $\geq 170$ mmHg
Absence of unstable clinical disease as determined by medical history	Medications that, in the opinion of the study physician or nurse practitioner, may impact the outcomes of the study (e.g., steroids)
	Cheyne-Stokes Respiration
	History or perforated eardrum
	History of glaucoma or retinopathy
	Pregnant, breastfeeding or trying to become pregnant (self-reported)

125 SBP= systolic blood pressure, DBP = diastolic blood pressure, mmHg = millimeters  
126 of mercury, mg/dl = milligrams per deciliter, kg = kilograms,  $\text{kg/m}^2$  = kilograms per  
127 meter squared  
128

129 **Eligibility Criteria**

130 Participants will be eligible for this study if they 1) are 18 years of age or older, 2) have  
131 been previously diagnosed with T2DM by a physician, 3) have a systolic BP between  
132 120-169 mmHg, 4) are on a stable dose of medication for at least 3 months, 5) do not  
133 have an unstable clinical disease, and 6) do not meet the exclusion criteria (Table 1).

134

135 **Interventions**

136 All training will be completed using the POWERbreathe™ K3 trainer (POWERbreathe  
137 International Ltd., Warwickshire, U.K.). This is a handheld pressure-threshold device  
138 with a computerized threshold sensor. Each participant will be provided their own  
139 device to perform IMST at home, 5 days/week for 6 weeks. They will receive in-person  
140 verbal instruction on the training protocol and K3 operation from the Research  
141 Technician at the start of the study.

142 The Research Technician will monitor one training session weekly in the CATS  
143 facility; the remaining 4 sessions will be completed unsupervised at home. During each  
144 visit to the CATS facility, the Research Technician will determine the participant's  
145 P<sub>I</sub>max and transfer the saved training data from the K3 device to ensure exercises are  
146 being completed at home. The P<sub>I</sub>max will be determined by taking the average of 3  
147 measurements. The Research Technician will then adjust the training resistance as  
148 needed to ensure participants are training at the prescribed intensity (i.e., either 15% or  
149 75% of P<sub>I</sub>max). The participant will then perform a supervised training session. All  
150 training sessions will be recorded in the device memory card, and participants also will  
151 be required to complete a weekly training log.

152

## 153 **Outcomes**

### 154 **Primary Outcomes**

#### 155 *Fasting Plasma Glucose and Fasting Serum Insulin*

156 Participants will report to the CATS facility at the University of Arizona following a  
157 12-hour fast for both the baseline and post-intervention visits. Up to 5 mL of blood will  
158 be drawn from the antecubital vein and sent to Sonora Quest for screening laboratory  
159 tests, lipid measures, and metabolic panels, including fasting plasma glucose and  
160 fasting serum insulin.

161

### 162 *Insulin Sensitivity*

163 Insulin sensitivity will be calculated using the Homeostatic Model assessment for  
164 insulin resistance (HOMA-IR), which is validated method of measuring insulin  
165 sensitivity [24]. The equation for HOMA-IR is:

166 
$$\text{fasting serum insulin } (\mu\text{IU/mL}) \times \text{fasting plasma glucose } (\text{mg/dL}) / 405.$$

167

### 168 **Secondary Outcomes**

#### 169 *Casual (Resting) Blood Pressure*

170 We will measure casual (resting) blood pressure per the American College of  
171 Cardiology (ACC) and the American Heart Association (AHA) guidelines [22] with an  
172 automated oscillometric sphygmomanometer (SunTech CT40, SunTech Medical).  
173 Briefly, participants will be asked to sit quietly with both feet flat on the ground, backs  
174 supported, and with their arms resting at heart level [22]. Three measures will be  
175 performed after a 5 minute quiet rest period with 1 minute of recovery between each  
176 measure. The average systolic and diastolic blood pressure will be recorded pre- and  
177 post-intervention.

178

#### 179 *Endothelial Dependent Dilatation*

180 Endothelial Dependent Dilatation (EDD) will be assessed via brachial artery flow-  
181 mediated dilatation (FMD) using high-resolution ultrasonography (Canon Xario 200G),  
182 as previously described [25]. Participants will be asked to avoid exercise, caffeine, and  
183 alcohol for 24 hours and food for at least 5 hours prior to their visit. FMD will be  
184 assessed by measuring the brachial artery diameter and blood velocity at baseline and  
185 for 3 minutes following reactive hyperemia, which stimulates NO release. Reactive



186 hyperemia is induced by 5 minutes of forearm blood flow occlusion with a cuff placed  
187 on the upper forearm and inflated at least 50 mmHg above systolic BP [22,26]. Brachial  
188 artery diameter and blood velocity will be analyzed offline using commercially  
189 available software (Brachial Analyzer, Medical Imaging Applications LLC, Coralville,  
190 IA, USA) [22] and expressed as absolute (mm) and percent change in arterial diameter  
191 from baseline (pre-cuff inflation diameter) to post-intervention following the 6 weeks  
192 of IMST.

193

## 194 **Exploratory Outcomes**

### 195 *Proteomic Analysis*

196 Blood will be collected into purple K2-EDTA vacutainers and immediately placed on  
197 ice, then centrifuged at 3,000 rpm at 4°C within 10 minutes of blood collection.  
198 Separated plasma will be removed and frozen at -80°C in cryotubes until analyzed using  
199 high-performance liquid chromatograph-electrospray ionization-MS/MS (LC-MS)  
200 [27]. Briefly, the extracted plasma proteins will be subjected to subsequent in-solution  
201 digestion using trypsin and Lys-C to be analyzed with tandem mass spectrometry  
202 [27,28]. Lastly, quantitative proteomics will be performed using extracted ion  
203 abundance, including statistical analysis via Progenesis [29]. The resulting quantitative  
204 proteomic data sets will be analyzed using DAVID for gene ontology and pathway  
205 enrichment analysis [30,31].

206

### 207 *DNA banking*

208 Blood will be collected from the antecubital vein of the arm directly into PAXgene  
209 DNA collection tubes, as per the manufacturer's instructions. Briefly, these tubes  
210 contain an additive reagent that stabilizes the blood. The tubes will sit at room

211 temperature for 2 hours and then be stored in the -20 freezer until processed. The  
 212 PAXgene DNA processing kit will be used to isolate the DNA. Once DNA is extracted,  
 213 it will be stored and banked for future studies. Participants will be required to provide  
 214 their consent for banking of their de-identified DNA/plasma samples.

215

## 216 **Participant timeline**

217 The timeline for participation in the study will be 7-9 weeks, as shown in Figure 1. A  
 218 summary of the visits for the DIT study participants is shown in Table 2.

219 **Table 2.** Summary of the Visits for the DIT Study

	<b>Baseline</b>		<b>Training</b>	<b>End-Intervention</b>	
	<b>Visit 1</b>	<b>Visit 2</b>	<b>Week 1-6</b>	<b>Visit 1</b>	<b>Visit 2</b>
<b>Screening</b>					
Informed Consent	X				
Demographics	X				
Medical History	X				
Inclusion/Exclusion	X				
Hip/waist/neck circumference	X			X	
<b>Functional Assessments</b>					
Casual BP	X			X	
PI <sub>max</sub>	X		X	X	
Spirometry	X			X	
<b>Blood Draw</b>					
Metabolic panel		X			X
Plasma / DNA		X			X
<b>Arterial Assessments</b>					
FMD <sub>BA</sub>	X			X	
<b>At-home Testing</b>					
Sleep/exercise diary			X		
<b>Exercise sessions</b>					
Daily exercise			X		
Once-weekly supervised			X		
Weekly text/email			X		
<b>Randomization</b>	X				

220 BP = Blood Pressure, FMD<sub>BA</sub> = Flow-mediated dilation of brachial artery, PI<sub>max</sub> =

221 Maximal inspiratory mouth pressure

222

223 Participants will sign a written informed consent with a member of the research team  
224 at the CATS facility. Following informed consent, participants will complete all  
225 baseline assessments in two in-person visits to the CATS facility within a 14-day  
226 window. Participants will begin the 6 week intervention  $\leq 14$  days after baseline  
227 assessments are completed. All assessments will be repeated within 14 days after  
228 completing the 6 week training program. Participants will continue to perform IMST 5  
229 days/week until all post-assessments are completed.

230

### 231 **Power analysis and sample size**

232 A minimum of 16 and a maximum of 24 participants will be enrolled and randomized  
233 into groups. To our knowledge, the effect of IMST, specifically 75% resistance, on  
234 fasting glucose and/or insulin sensitivity in any population has not previously been  
235 reported, nor have effects of IMST on systolic BP and EDD in T2DM been specifically  
236 ascertained. Thus, for our power analysis, we estimated a modest effect size of 0.40  
237 with alpha set at 0.05 using repeated measures ANOVA within-between framework. A  
238 sample size of 16-24 will have 85-96% power for any outcome with an effect size  $\geq$   
239 0.40.

240

### 241 **Recruitment**

242 Recruitment will be via word of mouth, advertisements placed in area newspapers,  
243 social media, and flyers posted around the University of Arizona and to the surrounding  
244 local community in Tucson. Interested individuals will be directed to the study website,  
245 where they will be able to complete a questionnaire to determine their eligibility.  
246 Individuals who do not meet the inclusion criteria will be informed of their ineligibility.  
247 Candidates who meet eligibility will be contacted for a study overview session.

248 After the study overview, written informed consent will obtained in person from  
249 each participant before the start of any study-related procedures. Ethical Approval for  
250 this study has been obtained from the University of Arizona Institutional Review Board  
251 (Protocol 00002239).

252

## 253 **Assignment of Interventions**

### 254 **Sequence generation**

255 The randomization sequence was created using computer-generated random numbers  
256 at a 1:1 ratio in blocks of four. Male and female participants will be randomized using  
257 separate randomization tables.

258

### 259 **Allocation concealment mechanism**

260 Group allocation will be stored in an Excel file that is not available to the Research  
261 Technician.

262

### 263 **Implementation**

264 Once the Research Technician has completed all enrollment activities for a participant  
265 (i.e., a participant has met the inclusion criteria and completed baseline assessments),  
266 the Principal Investigator (PI) will inform the research technician of the participant's  
267 allocation group.

268

### 269 **Blinding**

270 Due to the nature of the study, the participants are blinded to the intervention.

271

## 272 **Data Collection, Management, and Analysis**

## 273 **Data management**

274 Data will be collected with paper data collection forms and entered into a Microsoft  
275 Excel sheet within 48 hours of data collection. At the end of the study the Excel sheet  
276 will be rechecked against the paper originals and any inconsistencies will be noted and  
277 discussed between the PI and Research Technician in charge of data entry.

278

## 279 **Statistical plan**

280 Data will be analyzed with a repeated measures ANOVA test and Sidak post hoc testing  
281 using SPSS version 28.0. Group-by-sex interactions will be investigated, and effect  
282 sizes with confidence intervals will be reported in addition to p-values. All tests will be  
283 two-sided with alpha set at 0.05.

284

## 285 **Monitoring**

### 286 **Data monitoring**

287 The intervention is low-risk and does not require a data monitoring committee. The  
288 research team will meet with the study physician at regular intervals to track study  
289 progress and discuss any potential safety issues. No interim analyses will be performed.

290

### 291 **Harms**

292 An adverse event (AE) is any harmful and unintended reaction during the course of the  
293 study that may be related or unrelated to the intervention. All AEs occurring between a  
294 participant signing the informed consent and completing post-intervention assessments  
295 will be reported to the study physician.

296

## 297 **Anticipated Results**

298 **Primary Hypothesis**

299 Six weeks of high-resistance IMST will lower fasting plasma glucose and improve  
300 insulin sensitivity.

301

302 **Other Hypotheses**

303 Six weeks of high-resistance IMST will:

304 1. Lower causal (resting) systolic BP

305 2. Improve EDD

306

307 **Discussion**

308 Regular exercise is one of the most commonly prescribed non-pharmacological  
309 interventions for T2DM management and yields improvements in glycemic control and  
310 insulin action [7,8]. However, aerobic exercise is physically strenuous and time-  
311 consuming [10,11], and less than half of T2DM adults participate in exercise on a  
312 regular basis. In contrast, IMST is a novel form of high intensity training that can be  
313 performed whether sitting or standing, requires only 5 minutes per day, and rapidly  
314 improves blood pressure, endothelial vascular function, and vascular resistance among  
315 hypertensive adults [13,14,16,32]. Whether IMST can also affect changes in fasting  
316 blood glucose or insulin sensitivity is of critical interest and important for adults with  
317 T2DM, along with establishing if these blood pressure lowering effects and increased  
318 EDD are also seen in this population following IMST.

319 A study by Corrêa et al. studied the acute effects of IMST on glucose variability  
320 and showed significant improvements in glucose immediately following the training  
321 [33]. Additionally, another study, which was for 12 weeks at a lower resistance of 30%  
322 revealed no significant changes in blood glucose levels [34]. The discrepancies across

323 these findings are likely due to the populations studied, the timeframe of the training,  
324 and the resistance used. To our knowledge, there have been no investigations that have  
325 reported the effects of chronic IMST training at a resistance of 75% on glycemic control  
326 and insulin sensitivity in T2DM.

327 High-resistance IMST could yield long-term beneficial effects in T2DM  
328 patients, as it has in other populations [12,14,16,22,32]. We anticipate a reduction in  
329 fasting plasma glucose and improved insulin sensitivity while seeing similar established  
330 physiological benefits such as reduced systolic BP and improved endothelial function.

331

## 332 **Ethics and Dissemination**

### 333 **Research ethics approval**

334 This study has been approved by the University of Arizona Institutional Review Board  
335 (Approval Number: 00002239).

336

### 337 **Protocol amendments**

338 Any modifications to the protocol that may impact the conduct of the study will first be  
339 decided by the PI and approved by the University of Arizona IRB prior to any  
340 implementation. Administrative changes of the protocol are considered minor  
341 corrections that have no impact on the way the study is to be conducted. These changes  
342 will be agreed upon by the PI and documented.

343

### 344 **Consent**

345 This study will be thoroughly explained to each participant in person where subjects  
346 will have the opportunity to ask questions. Once the member of the research team

347 believes the participant understands the study requirements, they will be directed to  
348 read and sign the informed consent document.

349

### 350 **Confidentiality**

351 Identity of the participants will be protected by assigning each a code (i.e., a 3-digit  
352 number) and any experimental data collected from these subjects will be recorded under  
353 that number. Any identifiable personal information will be kept in a password-protected  
354 digital file and/or in a locked cabinet. Only the PI, Co-I and Research Technician will  
355 have access to the information.

356

### 357 **Declaration of interests**

358 There are no conflicts of interest associated with the study and research team.

359

### 360 **Access to data**

361 The PI, Co-I and Research Technician will have access to the final trial dataset. Other  
362 project team members will be provided de-identified data for their analysis.

363

### 364 **Ancillary and post-trial care**

365 There are no provisions for ancillary or post-trial care.

366

### 367 **Dissemination policy**

368 Primary outcome papers will be approved by the PI prior to journal submission. Every  
369 attempt will be made to release study results to the general public soon after study  
370 completion. Interim and final reports may also be presented at various local, regional,  
371 and international conferences, with approval from the PI. Eligibility for authorship



372 include (1) substantial contribution to study conception and design AND/OR  
373 substantial contributions to acquisition analysis or interpretation of data, AND (2)  
374 drafting or revising the manuscript, AND (3) final approval of the manuscript. There is  
375 no intention to use professional writers.

376

## 377 **Acknowledgments**

378 We thank our nursing staff Alma D. Leon, R.N. and Judith Krentzel, N.P. for their  
379 review of the DIT protocols.

380


## 381 **References**

- 382 1. Center for Disease Control and Prevention. National Diabetes Statistics  
383 Report website. [Internet]. [cited 2023 Jul 12]. Available from:  
384 <https://www.cdc.gov/diabetes/data/statistics-report/index.html>
- 385 2. Yang W, Dall TM, Beronjia K, Lin J, Semilla AP, Chakrabarti R, et al. Economic  
386 Costs of Diabetes in the U.S in 2017. *Diabetes Care* 2018. 2018 Mar  
387 22;41(5):917–28.
- 388 3. Abdul-Ghani MA, DeFronzo RA. Mitochondrial dysfunction, insulin resistance,  
389 and type 2 diabetes mellitus. *Curr Diab Rep*. 2008 Jun;8(3):173–8.
- 390 4. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-Cell  
391 Deficit and Increased  $\beta$ -Cell Apoptosis in. 2003;52.
- 392 5. Jay Widmer R, Lerman A. Endothelial dysfunction and cardiovascular disease.  
393 *Glob Cardiol Sci Pract*. 2014 Oct;2014(3):43.
- 394 6. Venables MC, Jeukendrup AE. Physical inactivity and obesity: links with  
395 insulin resistance and type 2 diabetes mellitus. *Diabetes Metab Res Rev*. 2009  
396 Sep;25(S1):S18–23.
- 397 7. Kirwan JP, Sacks J, Nieuwoudt S. The essential role of exercise in the  
398 management of type 2 diabetes. *Cleve Clin J Med*. 2017 Jul;84(7 suppl 1):S15–  
399 21.
- 400 8. Borghouts LB, Keizer HA. Exercise and Insulin Sensitivity: A Review. *Int J*  
401 *Sports Med*. 2000 Jan;21(1):1–12.
- 402 9. Mu L, Cohen AJ, Mukamal KJ. Resistance and Aerobic Exercise Among Adults  
403 With Diabetes in the U.S. *Diabetes Care*. 2014 Aug 1;37(8):e175–6.

- 404 10. Korhakangas EE, Alahuhta MA, Husman PM, Keinänen-Kiukaanniemi S,  
405 Taanila AM, Laitinen JH. Motivators and barriers to exercise among adults  
406 with a high risk of type 2 diabetes - a qualitative study: Motivators and  
407 barriers to exercise among adults. *Scand J Caring Sci.* 2011 Mar;25(1):62–9.
- 408 11. Kelly S, Martin S, Kuhn I, Cowan A, Brayne C, Lafortune L. Barriers and  
409 Facilitators to the Uptake and Maintenance of Healthy Behaviours by People  
410 at Mid-Life: A Rapid Systematic Review. Wang Y, editor. *PLOS ONE.* 2016 Jan  
411 27;11(1):e0145074.
- 412 12. Vranish JR, Bailey EF. Inspiratory Muscle Training Improves Sleep and  
413 Mitigates Cardiovascular Dysfunction in Obstructive Sleep Apnea. *Sleep.*  
414 2016 Jun 1;39(6):1179–85.
- 415 13. Craighead DH, Tavoian D, Freeberg KA, Mazzone JL, Vranish JR, DeLucia CM,  
416 et al. A multi-trial, retrospective analysis of the antihypertensive effects of  
417 high-resistance, low-volume inspiratory muscle strength training. *J Appl*  
418 *Physiol.* 2022 Oct 1;133(4):1001–10.
- 419 14. Craighead DH, Heinbockel TC, Freeberg KA, Rossman MJ, Jackman RA,  
420 Jankowski LR, et al. Time-Efficient Inspiratory Muscle Strength Training  
421 Lowers Blood Pressure and Improves Endothelial Function, NO  
422 Bioavailability, and Oxidative Stress in Midlife/Older Adults With  
423 Above-Normal Blood Pressure. *J Am Heart Assoc.* 2021 Jul 6;10(13):e020980.
- 424 15. Leon BM. Diabetes and cardiovascular disease: Epidemiology, biological  
425 mechanisms, treatment recommendations and future research. *World J*  
426 *Diabetes.* 2015;6(13):1246.
- 427 16. Ramos-Barrera GE, DeLucia CM, Bailey EF. Inspiratory muscle strength  
428 training lowers blood pressure and sympathetic activity in older adults with  
429 OSA: a randomized controlled pilot trial. *J Appl Physiol.* 2020 Sep  
430 1;129(3):449–58.
- 431 17. Fornoni A, Raij L. Metabolic syndrome and endothelial dysfunction. *Curr*  
432 *Hypertens Rep.* 2005 Mar;7(2):88–95.
- 433 18. Sansbury BE, Hill BG. Regulation of obesity and insulin resistance by nitric  
434 oxide. *Free Radic Biol Med.* 2014 Aug;73:383–99.
- 435 19. Bahadoran Z, Mirmiran P, Ghasemi A. Role of Nitric Oxide in Insulin Secretion  
436 and Glucose Metabolism. *Trends Endocrinol Metab.* 2020 Feb;31(2):118–30.
- 437 20. Hartge MM, Unger T, Kintscher U. The endothelium and vascular  
438 inflammation in diabetes. *Diab Vasc Dis Res.* 2007 Jun;4(2):84–8.
- 439 21. Suzuki T, Hirata K, Elkind MSV, Jin Z, Rundek T, Miyake Y, et al. Metabolic  
440 syndrome, endothelial dysfunction, and risk of cardiovascular events: The  
441 Northern Manhattan Study (NOMAS). *Am Heart J.* 2008 Aug;156(2):405–10.

- 442 22. Tavoian D, Ramos-Barrera LE, Craighead DH, Seals DR, Bedrick EJ, Alpert JS,  
443 et al. Six Months of Inspiratory Muscle Training to Lower Blood Pressure and  
444 Improve Endothelial Function in Middle-Aged and Older Adults With Above-  
445 Normal Blood Pressure and Obstructive Sleep Apnea: Protocol for the CHART  
446 Clinical Trial. *Front Cardiovasc Med*. 2021 Nov 24;8:760203.
- 447 23. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes  
448 by flow-mediated vasodilatation of brachial artery: a meta-analysis. *Int J*  
449 *Cardiovasc Imaging*. 2010 Aug;26(6):631–40.
- 450 24. Matthews DR, Hosker JR, Rudenski AS, Naylor BA, Treacher DF, Turner RC, et  
451 al. Homeostasis model assessment: insulin resistance and  $\beta$ -cell function  
452 from fasting plasma glucose and insulin concentrations in man.
- 453 25. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan  
454 ID, et al. Non-invasive detection of endothelial dysfunction in children and  
455 adults at risk of atherosclerosis. *The Lancet*. 1992 Nov;340(8828):1111–5.
- 456 26. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager  
457 MA, et al. Guidelines for the Ultrasound Assessment of Endothelial-  
458 Dependent Flow-Mediated Vasodilation of the Brachial Artery. *J Am Coll*  
459 *Cardiol*. 2002 Jan;39(2):257–65.
- 460 27. Harney DJ, Hutchison AT, Hatchwell L, Humphrey SJ, James DE, Hocking S, et  
461 al. Proteomic Analysis of Human Plasma during Intermittent Fasting. *J*  
462 *Proteome Res*. 2019 May 3;18(5):2228–40.
- 463 28. Kruse R, Krantz J, Barker N, Coletta RL, Rafikov R, Luo M, et al.  
464 Characterization of the CLASP2 Protein Interaction Network Identifies  
465 SOGA1 as a Microtubule-Associated Protein. *Mol Cell Proteomics*. 2017  
466 Oct;16(10):1718–35.
- 467 29. James J, Valuparampil Varghese M, Vasilyev M, Langlais PR, Tofovic SP,  
468 Rafikova O, et al. Complex III Inhibition-Induced Pulmonary Hypertension  
469 Affects the Mitochondrial Proteomic Landscape. *Int J Mol Sci*. 2020 Aug  
470 8;21(16):5683.
- 471 30. Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web  
472 server for functional enrichment analysis and functional annotation of gene  
473 lists (2021 update). *Nucleic Acids Res*. 2022 Jul 5;50(W1):W216–21.
- 474 31. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of  
475 large gene lists using DAVID bioinformatics resources. *Nat Protoc*. 2009  
476 Jan;4(1):44–57.
- 477 32. DeLucia CM, De Asis RM, Bailey EF. Daily inspiratory muscle training lowers  
478 blood pressure and vascular resistance in healthy men and women. *Exp*  
479 *Physiol*. 2018 Feb 1;103(2):201–11.
- 480 33. Corrêa APS, Figueira FR, Umpierre D, Casali KR, Schaan BD. Inspiratory  
481 muscle loading: a new approach for lowering glucose levels and glucose

- 482           variability in patients with Type 2 diabetes. *Diabet Med.* 2015  
483           Sep;32(9):1255–7.
- 484    34. Pinto MB, Bock PM, Schein ASO, Portes J, Monteiro RB, Schaan BD.  
485           Inspiratory Muscle Training on Glucose Control in Diabetes: A Randomized  
486           Clinical Trial. *Int J Sports Nutr Exerc Metab.* 2020 Nov 27;31(1):21–31.
- 487



Figure